News and Education for health professionals

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

For more information, visit https://www.boehringer-ingelheim.com.au


Renal impairment and glucose management in type 2 diabetes

Type 2 diabetes is a serious health issue with around one million diagnosed cases, of which half are also affected from renal impairment. This education module explores the pharmacological and non-pharamacological management of type 2 diabetes and its comorbities, with a focus on management options in patients with renal impairment.

Upon completion of this learning module, participants will be able to: